Angela Corona

Angela Corona graduated in Pharmaceutical Chemistry at the University of Cagliari in 2010 and earned in 2014 a PhD in Biology and Biochemistry. She was Guest Researcher in 2011/2012 at the Drug Resistance Program, Center for Excellence in HIV / AIDS and Cancer Virology, Center for Cancer Research at the National Cancer Institute, MD, USA and in 2013 at the Laboratoire de Biologie et Pharmacologie appliquée, Ecole Normale Superieure de Cachan, Paris.Since 2020 she is assistant professor at Department of Life and Environmental Sciences at the University of Cagliari. From 2015 to 2020 she was a post-doctoral researcher at the Molecular Virology Laboratory of the Department of Life and Environmental Sciences at the University of Cagliari. In 2017 she was Research Fellow at the IrsiCaixaAIDS Research Institute, Hospital Germans Trias and Pujol, Barcelona, granted by Chu Family Foundation (CFF) Women Scientists Award. Since 2020 she was an Assistant Professor and since 2023 she is an associated professor at the Faculty of Biology and Pharmacy, Department of Life and Environmental Sciences, Section of Molecular Virology, University of Cagliari (Italy). Angela is a molecular virologist whose research activity has different topics related to the identification and characterization of the mechanism of action of antiviral molecules with different targets: she started her antiviral research activity working on the ribonuclease-H function associated with the HIV-1 reverse transcriptase. She also investigates the pathological roles of viral proteins to validate novel targets for drug development. In particular, she focused on Ebola virus proteins involved in the inhibition of innate immune response (VP35 and VP24 proteins). Her expertise in biochemical assays is coupled with expertise in the evaluation of antiviral activity in cell-based assays for Class 2 and Class 3 viral agents. Recently she has been involved in several grants regarding Coronaviruses, as in the EU-granted project EXSCALATE4CoV (E4C), a 2020 tender for projects to counter the Coronavirus pandemic and improve the management and care of patients (https://www.exscalate4cov.eu/). For her research activities, she was awarded the “Cecilia Cioffrese- Malattie Virali 2016” prize by the Carlo Erba Foundation. Her work has resulted in 78 publications including papers and book chapters. She is part of the editorial board of Frontiers as Review Editor in Experimental Pharmacology and Drug Discovery and in Antivirals and Vaccines.